Literature DB >> 15117334

Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours.

M Venihaki1, S Sakihara, S Subramanian, P Dikkes, S C Weninger, G Liapakis, T Graf, J A Majzoub.   

Abstract

Following its discovery 20 years ago, corticotropin-releasing hormone (CRH) has been postulated to mediate both hormonal and behavioural responses to stressors. Here, we characterize and describe a behavioural role for the murine gene, UcnIII, which encodes a recently discovered CRH-related neuropeptide, urocortin III. We found that mouse UcnIII is expressed predominantly in regions of the brain known to be involved in stress-related behaviours, and its expression in the hypothalamus increases following restraint. In addition, we found that intracerebroventricular administration of mUcnIII stimulates behaviours that are associated with reduced anxiety, including exploration of an open field and decreased latency to enter the lit compartment of a dark-light chamber, but has no effect on the elevated-plus maze. Finally, we found that mUcnIII does not exert any effects on the hormonal stress response. Based upon our findings, UcnIII may be an endogenous brain neuropeptide that is modulated by stress and stimulates behaviours associated with reduced anxiety. In this capacity, UcnIII may attenuate stress-related behaviours, which may be useful both to help cope with stressful situations as well as to avoid pathology associated with excessive reaction to stressors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117334     DOI: 10.1111/j.1365-2826.2004.01170.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  35 in total

1.  Perifornical Urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis.

Authors:  Yael Kuperman; Orna Issler; Limor Regev; Ifat Musseri; Inbal Navon; Adi Neufeld-Cohen; Shosh Gil; Alon Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

2.  Distribution and axonal projections of neurons coexpressing thyrotropin-releasing hormone and urocortin 3 in the rat brain.

Authors:  Gábor Wittmann; Tamás Füzesi; Zsolt Liposits; Ronald M Lechan; Csaba Fekete
Journal:  J Comp Neurol       Date:  2009-12-20       Impact factor: 3.215

Review 3.  Urocortins: CRF's siblings and their potential role in anxiety, depression and alcohol drinking behavior.

Authors:  Andrey E Ryabinin; Michael M Tsoory; Tamas Kozicz; Todd E Thiele; Adi Neufeld-Cohen; Alon Chen; Emily G Lowery-Gionta; William J Giardino; Simranjit Kaur
Journal:  Alcohol       Date:  2012-03-22       Impact factor: 2.405

4.  Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.

Authors:  Eva M Fekete; Koki Inoue; Yu Zhao; Jean E Rivier; Wylie W Vale; Attila Szücs; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2006-10-04       Impact factor: 7.853

Review 5.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 6.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

7.  Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes.

Authors:  Lacey L Sahuque; Erika F Kullberg; Andrew J Mcgeehan; Jennifer R Kinder; Megan P Hicks; Mary G Blanton; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2006-03-28       Impact factor: 4.530

8.  Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis.

Authors:  Peilin Chen; Joan Vaughan; Cindy Donaldson; Wylie Vale; Chien Li
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-01       Impact factor: 4.310

9.  Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal.

Authors:  Francesco Papaleo; Sandy Ghozland; Manuela Ingallinesi; Amanda J Roberts; George F Koob; Angelo Contarino
Journal:  Neuropsychopharmacology       Date:  2008-02-20       Impact factor: 7.853

10.  Effects of acidic-astressin and ovine-CRF microinfusions into the ventral hippocampus on defensive behaviors in rats.

Authors:  Nathan S Pentkowski; Yoav Litvin; D Caroline Blanchard; Amy Vasconcellos; Lanikea B King; Robert J Blanchard
Journal:  Horm Behav       Date:  2009-03-06       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.